use of NGS in pancreatic cancer, the Foundry platform now gives us the ability to analyze large datasets comprising real-world clinical and molecular information to dissect the heterogeneity ofKRAS-mutated pancreatic cancer. In this study, we illustrate the co-mutation landscape ofKRASmutations and t...
Mariano Barbacid’s group first established the relationship betweenRASgenes and lung cancer in 1984. They conducted a landmark study which evidenced the presence of an activating mutation ofKRASoncogene in a human lung cancer specimen that was not observed in normal tissue of the same patient [2...
Intersecting evidence: Bibliometric analysis and clinical trials illuminate immunotherapy in KRAS-mutation cancer: A reviewdoi:10.1097/MD.0000000000039334Citespaceclinical trialsimmunotherapyKRASscientometric analysistargeted therapyvaccineKRAS mutations play a critical role in the development and progression of ...
European Journal of Cancer 29 January 2024 Backgrounds: Sotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were prom...
KRASis the most commonly mutated oncogene in human cancer, with particularly high frequency in cancers of the pancreas, colon, and lung. KRASmutation is associated with poor prognosis, yet there are no effective therapies to specifically treat cancers expressing mutant forms of the KRAS oncoprotein....
et al.The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (...
, prostate cancer (PC-3), ovarian cancer (COV362) cell lines and a normal colon cell line (CCD841CoN) were resistant to vitamin C when used both as a single agent and in combination with STS (Fig.1b). In agreement with the selective toxicity of STS + vitamin C inKRAS-mutant ...
mutations of KRAS-related molecules, in these three specific cancer types. CRISPR applications in clinical trials of lung, pancreas and colon cancers Although CRISPR has been tested in the editing of genes responsible for various diseases, its application in cancer at clinical level is still new. ...
Erbitux (Erbitux, cetuximab and panitumumab) (Panitumumab) applies only to thewild type K-RAS gene in patients with no mutations, mutation of K-RAS patientsis invalid. The national comprehensive cancer network (NCCN) classified theK-RAS test as a guideline for clinical treatment of colon cancer...
比如Memorial Sloan Kettering Cancer Center的Lito, Piro目前在研的2项课题,专注于肿瘤耐药信号相关的的研究: 1) Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance 2) Dissecti...